TABLE 1.
Baseline characteristic of the included studies
| Author | Sampling, T/C | Age, T/C | Intervention, T/C | Duration, outcomes |
|---|---|---|---|---|
|
Bai et al. (Yu., 2016) |
58/52 |
58.55.±.7.02 61.78 ± 9.01 |
UK.+.E,.0.15 PNA, 1/day E, 30 mg, 2/day |
14 days, NIHSS, ADL, Total effective rate |
|
Zhang et al. (Wen, 2019) |
54/54 |
62.34 ± 4.98 62.28 ± 4.76 |
UK + E,0.15 PNA, 1/day E,30 mg, 1/day |
14 days, NIHSS, ADL, Total effective rate |
|
Yang et al. (Yubo, 2016) |
47/47 |
— — |
UK + E, 0.15 PNA, 1/day E, 30 mg, 1/day |
14 days, NIHSS, ADL, Total effective rate |
|
Hu et al. (Haibing, 2017) |
45/45 |
61.73 ± 6.59 61.25 ± 6.40 |
UK + E, 0.15U, 1/day E, 30 mg, 1/12h |
14 days, NIHSS, ADL, Total effective rate |
|
Ao et al. (Aojinjiang, 2017) |
45/45 |
62.30 ± 7.20 65.30 ± 7.80 |
UK + E,0.15 PNA,1/day E, 30 mg, 2/day |
14 days, NIHSS, ADL, Total effective rate |
|
Lai et al. (Suiping, 2015) |
34/33 |
65.01 ± 10.72 59.65 ± 8.91 |
UK + E, 0.15 PNA, 1/day E, 30 mg, 2/day |
14 days, NIHSS, ADL, Total effective rate |
|
Wang et al. (Hongjun, 2019) |
58/58 |
63.47 ± 4.15 62.42 ± 4.17 |
UK + E, 0.15 mg, 1/day E, 30 mg, 2/day |
14 days, NIHSS, ADL, Total effective rate |
|
Wang et al. (Hong, 2016) |
48/48 |
60.39 ± 8.23 61.05 ± 8.29 |
UK + E, 0.15 PNA, 1/day E, 30 mg, 1/day |
14 days, NIHSS, ADL, Total effective rate |
|
Wang et al. (Wang Jing, 2017) |
50/50 |
— — |
UK + E, 0.15 mg, 1/day E, 30 mg, 2/day |
14 days, NIHSS, ADL, Total effective rate |
|
Xi et al. (Na, 2020) |
56/41 |
63.80 ± 11.40 67.50 ± 10.20 |
UK + E, 0.15 mg, 1/day E, 30 mg, 2/day |
14 days, NIHSS, ADL, Total effective rate |
|
Yang et al. (Xinli, 2019) |
57/57 |
68.20 ± 3.30 68.80 ± 3.10 |
UK + E,0.15 PNA, 1/day E,3 0 mg, 1/day |
14 days, NIHSS, ADL, Total effective rate |
|
Jiang et al. (Bingquan, 2016) |
35/35 |
63.34 ± 2.56 63.74 ± 2.48 |
UK + E, 0.15 PNA, 2/day E,0.03 g, 2/day |
14 days, NIHSS, ADL, Total effective rate |
|
Deng et al. (Menglin, 2017) |
45/45 |
61.80 ± 6.70 61.40 ± 6.41 |
UK + E, 0.15 PNA, 1/day E, 0.03 g, 2/day |
14 d, NIHSS, ADL, Total effective rate |
Abbreviations: ADL, activities of daily living; C, control; E, edaravone; NIHSS, National Institutes of Health Stroke Scale; T, treatment; UK + E, urinary kallidinogenase + edaravone.